GP6 and thrombotic disease: Therefore, several GPVI inhibitors and blocking antibodies have been developed and evaluated in preclinical models or clinical trials of patients with thrombotic diseases to target GPVI functions, thereby inhibiting thrombus formation [11,28,29].